NCT02581527View on ClinicalTrials.gov

A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis

PHASE3CompletedINTERVENTIONAL
Enrollment

672

Participants

Timeline

Start Date

February 1, 2017

Primary Completion Date

January 1, 2022

Study Completion Date

July 31, 2022

Conditions
Pulmonary Tuberculosis
Interventions
DRUG

Rifampicin

Rifampicin 150mg (Control arm); Rifampicin 1200mg (Regimen 1); Rifampicin 1800mg (Regimen 2)

DRUG

Isoniazid

Isoniazid 75mg - all arms

DRUG

Ethambutol

Ethambutol 275mg - all arms

DRUG

Pyrazinamide

Pyrazinamide 400mg - all arms

Trial Locations (6)

Unknown

University of Botswana, Gaborone

Hopital National Ignace Deen, Conakry

GENETUP, National Anti-TB Association, Kathmandu

Aga Khan University Hospital, Karachi

Hospital Nacional Dos de Mayo, Lima

Epicentre, Mbarara

All Listed Sponsors
collaborator

London School of Hygiene and Tropical Medicine

OTHER

collaborator

University of Botswana

OTHER

lead

St George's, University of London

OTHER

NCT02581527 - A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis | Biotech Hunter | Biotech Hunter